Sandy Gibson shares a personal update two months into taking tirzepatide and weighs whether it is doing its job.
Recap by typeshit. Full story at Sandy Gibson.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Healio
At a Boston masterclass, the Harvard obesity doctor said GLP-1s should be treated as indefinite care, since weight returns when they stop.
Researchers suggest Ozempic and Wegovy could influence hiring decisions and workplace productivity as more Americans take them.
Loading…